Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols

Zeba N Singh; Yogesh Jethava; Ginell R Post; Daisy Alapat; Jeffrey Sawyer; Sarah Waheed; Bijay Nair; Saad Z Usmani; Clyde Bailey; Nathan Petty; Frits Van Rhee; Bart Barlogie

doi:10.1002/ccr3.180

Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols

Clin Case Rep. 2015 Mar;3(3):183-92. doi: 10.1002/ccr3.180. Epub 2015 Feb 13.

Authors

Affiliations

¹ Department of Pathology, University of Arkansas for Medical Sciences 4301 W. Markham Street Slot 502, Little Rock, Arkansas, 72205.
² Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences 4301 West Markham Slot 816, Little Rock, Arkansas, 72205.

Abstract

Assiduous surveillance for genetic aberrations is necessary in patients on cytotoxic therapies to detect therapy-related myeloid neoplasms (t-MN). Current modalities include metaphase cytogenetics and FISH. Since t-MN may develop abruptly in cytogenetically normal patients, a discussion exploring additional methods such as SNP-array and targeted-deep-sequencing to detect subchromosomal abnormalities is needed.

Keywords: Acute leukemia; cytogenetic abnormalities; myeloma; therapy-related myeloid neoplasm.

Publication types

Case Reports